MoonLake Immunotherapeutics
Stock Forecast, Prediction & Price Target
MoonLake Immunotherapeutics Financial Estimates
MoonLake Immunotherapeutics Revenue Estimates
MoonLake Immunotherapeutics EBITDA Estimates
MoonLake Immunotherapeutics Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| $0 N/A | $0 0% | $0 0% | Avg: $0 Low: $0 High: $0 avg. 0% | Avg: $0 Low: $0 High: $0 avg. 0% | Avg: $132.79M Low: $132.79M High: $132.79M avg. 0% | Avg: $653.40M Low: $653.40M High: $653.40M avg. 392.02% |
Net Income
% change YoY
| $-53.64M N/A | $-64.50M -20.24% | $-36.00M 44.18% | Avg: $-110.53M Low: $-137.54M High: $-34.38M avg. -206.97% | Avg: $-158.40M Low: $-169.47M High: $-35.36M avg. -43.30% | Avg: $-130.86M Low: $-130.86M High: $-130.86M avg. 17.38% | Avg: $83.31M Low: $83.31M High: $83.31M avg. 163.66% |
EBITDA
% change YoY
| $-53.57M N/A | $-65.06M -21.44% | $-54.10M 16.83% | Avg: $0 Low: $0 High: $0 avg. 100% | Avg: $0 Low: $0 High: $0 avg. 0% | Avg: $0 Low: $0 High: $0 avg. 0% | Avg: $0 Low: $0 High: $0 avg. 0% |
EPS
% change YoY
| -$6.84 N/A | -$2.2 67.83% | -$0.73 66.81% | Avg: -$1.8 Low: -$2.8 High: -$0.7 avg. -146.31% | Avg: -$2.41 Low: -$3.45 High: -$0.72 avg. -33.95% | Avg: -$2.66 Low: -$2.66 High: -$2.66 avg. -10.60% | Avg: $1.7 Low: $1.7 High: $1.7 avg. 163.66% |
Operating Expenses
% change YoY
| $53.57M N/A | $65.06M 21.44% | $54.12M -16.81% | Avg: $0 Low: $0 High: $0 avg. -100% | Avg: $0 Low: $0 High: $0 avg. 0% | Avg: $0 Low: $0 High: $0 avg. 0% | Avg: $0 Low: $0 High: $0 avg. 0% |
FAQ
What is MoonLake Immunotherapeutics stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of -17.30% in 2025-2028.
We have gathered data from 9 analysts. Their low estimate is -137.54M, average is -110.53M and high is -34.38M.
What is MoonLake Immunotherapeutics stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 98.00% in 2025-2028.
We have gathered data from 10 analysts. Their low revenue estimate is N/A, average is N/A and high is N/A.
What is MoonLake Immunotherapeutics stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of -6.80% in 2025-2028.
We have gathered data from 9 analysts. Their low earnings per share estimate is -$2.8, average is -$1.8 and high is $-0.7.
What is the best performing analyst?
In the last twelve months analysts have been covering MoonLake Immunotherapeutics stock. The most successful analyst is Raghuram Selvaraju whose win rate is 50%. He has correctly predicted 1/2 price targets.